---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-003011"
form_type: "8-K"
ticker: null
cik: "0001293310"
company_name: "HUMANIGEN, INC"
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:33:11.998492+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Humanigen receives Nasdaq delisting notice; settles Avid dispute for $3M

## Summary
- Nasdaq notified Humanigen it failed to regain minimum bid price compliance by Feb 20, 2023; not eligible for second extension.
- Company also fails stockholders' equity initial listing requirement and market value below $35M for continued listing.
- Company intends to request a hearing before Nasdaq Hearings Panel by Feb 28, 2023; stay of suspension pending hearing.
- Settled Lenzilumab disputes with Avid Bioservices for $3.0M one-time payment; conditional dismissal after 120 days if no bankruptcy.

## SEC filing metadata
- accession: 0001214659-23-003011
- form_type: 8-K
- cik: 0001293310
- company_name: HUMANIGEN, INC
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/0001214659-23-003011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/g2232308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-003011
- JSON: https://secwatch.observer/filing/0001214659-23-003011.json
- Plain text: https://secwatch.observer/filing/0001214659-23-003011.txt

## Key facts
- Listing & Compliance Notices
  HUMANIGEN, INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/0001214659-23-003011-index.htm
- Listing & Compliance Notices
  HUMANIGEN, INC received a nasdaq delisting notice notice regarding stockholders equity.
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  source text: February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/0001214659-23-003011-index.htm
- Listing & Compliance Notices
  HUMANIGEN, INC received a nasdaq delisting notice notice regarding market value.
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  source text: February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/0001214659-23-003011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.